Items Tagged ‘Lung Cancer’

November 8th, 2016

Personalized Lung Cancer Care & Precision Medicine

By

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by finding the genetic alterations within the cancer that drive its growth and then use medicines that specifically counteract […]

View full entry

Tags: Alcensa, ALK mutation, EGFR, General Lung Cancer, gilotrif, iressa, Lung Cancer, Lung Cancer - Non-Small Cell, Lung Cancer - Small Cell, Necitumumab, News, nsclc


October 27th, 2016

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing

By

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with advanced stage lung cancer still die from their disease. Precision medicine continues to impact the lives […]

View full entry

Tags: General Lung Cancer, immune response, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nivolumab, nsclc, opdivo, PD-1 inhibitors, pembrolizumab, precision medicine


October 25th, 2016

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer

By

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such as Keytruda […]

View full entry

Tags: fda, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell


October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


October 19th, 2016

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer

By

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study was also recently published in the New England Journal of Medicine evaluating Keytruda in previously treated patients with advanced NSCLC . Results of […]

View full entry

Tags: 2016, advanced, ESMO, General Lung Cancer, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, opdivo, PD-1, pembrolizumab


September 14th, 2016

FDA Grants Breakthrough Therapy Designation to Keytruda® for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Keytruda® (pembrolizumab) for first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). The FDA’s Breakthrough Therapy Designation is intended to expedite the development and review of a drug that is planned for use to treat a serious or life-threatening disease […]

View full entry

Tags: advanced, General Lung Cancer, KEYNOTE-024, Lung Cancer, Lung Cancer - Non-Small Cell, Merck, News, nsclc, pembrolizumab, Stages IIIB-IV Lung Cancer - Non-Small Cell


September 13th, 2016

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer

By

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled trial of its kind. As many as 30% of all patients with NSCLC will present with or develop brain metastases. There is currently a routine practice […]

View full entry

Tags: advanced, brain metastases, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, nsclc, QUARTZ, Recurrent Lung Cancer - Non-Small Cell, Stages IIIB-IV Lung Cancer - Non-Small Cell, surgery, WBRT


June 7th, 2016

First Targeted Therapy Shows Promise in Small Cell Lung Cancer

By

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be substantial, long-term survival for patients with SCLC remains poor. Survival in SCLC is no more than 15%, 2 […]

View full entry

Tags: antibody-drug conjugate, DLL3, Lung Cancer, Lung Cancer - Non-Small Cell, News, Recurrent Lung Cancer - Non-Small Cell, Rova-T, Rovalpituzumab tesirine, sclc, small cell lung cancer, targeted therapy


June 6th, 2016

PD-1 Inhibitor Keytruda® Combined with Chemotherapy Promising in Lung Cancer Will be Evaluated in Larger Clinical Trials

By

According to experts at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, new data evaluating Keytruda® (pembrolizumab) in combination with chemotherapy appears promising for the treatment of non-small cell lung cancer (NSCLC). Based on these initial results, two comparative clinical trials have been initiated. The programmed death (PD-1) inhibitor Keytruda (pembrolizumab) […]

View full entry

Tags: fda, immunotherapy, KEYNOTE-189, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, PD-1 inhibitor, pembrolizumab


June 6th, 2016

Two-Drug Immunotherapy Deemed Safe for Small Cell Lung Cancer Patients, Moffitt Study Shows

By

Small cell lung cancer (SCLC) represents approximately 14 percent of all types of lung cancer. Many patients with SCLC respond to initial chemotherapy; however, they eventually relapse and develop progressive disease that has no effective treatment options. A new Moffitt Cancer study being presented at the ASCO Annual Meeting in Chicago and published in The […]

View full entry

Tags: 2016, asco, Checkmate 032, immunotherapy, ipilmumab, Lung Cancer, Lung Cancer - Small Cell, molecule PD-1, News, nivolumab, sclc, small cell lung cancer


May 9th, 2016

Another Study Confirms That Daily Aspirin Lowers Risk of Colorectal & Other GI Tract Cancers

By

The regular use of aspirin significantly reduces the overall risk of cancer, especially colorectal and other gastrointestinal tract cancers, according to a study published in JAMA Oncology.1 The recent report supports the results of previous clinical studies that have also demonstrated that the daily use of aspirin reduces the risk of death from several common cancers, including lung, […]

View full entry

Tags: aspirin, benefit, cancer, Colon Cancer, colorectal, daily, Esophageal Cancer, gastrointestinal, lung, Lung Cancer, News, Rectal Cancer


March 29th, 2016

Xalkori® Approved for Lung Cancer with ROS-1 Gene Alterations

By

The United States Food and Drug Administration (FDA) approved Xalkori (crizotinib) as treatment for patients with advanced non-small cell lung cancer (NSCLC) whose cancer has an alteration within the ROS-1 gene. Xalkori is already approved for the treatment of patients with NSCLC that have a mutation in the anaplastic lymphoma kinase (ALK) gene. Lung cancer […]

View full entry

Tags: clinical trial, crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, ROS-1 gene, xalkori


December 24th, 2015

Alecensa ™ Approved for the Treatment of Recurrent ALK-Positive Lung Cancer

By

The FDA approved another inhibitor of anaplastic lymphoma kinase (ALK) for treatment of non-small cell lung cancer (NSCLC) today, further expanding precision treatment options. Alecensa ™ (Alectinib) is indicated for advanced, metastatic, ALK-positive NSCLC in patients unresponsive to or intolerant of another ALK inhibitor, Xalkori ™ (crizotinib). The investigative agent, Alecensa, produces high anti-cancer responses […]

View full entry

Tags: Alecensa, alectinib, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc


November 19th, 2015

Novel Precision Medicine Tagrisso Approved for Treatment of Lung Cancer

By

The United States Food and Drug Administration (FDA) has approved Tagrisso (osimertinib) for the treatment of lung cancer with the epidermal growth factor receptor (EGFR) T790M mutation. The indication specifies that patients must have non-small cell lung cancer (NSCLC) that has progressed despite treatment with other approved agents that block the EGFR pathway. The diagnostic […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, osimertinib, T790M mutation, tagrisso


November 16th, 2015

New Lab Test Enables Precision Treatment for Lung Cancer

By

The complementary laboratory test that measures PD-L1 levels among patients with lung cancer who are to receive treatment with Opdivo® (nivolumab), is now available for commercial use and can help guide more precise therapy for lung cancer. Lung cancer is the most common cause of cancer-related deaths in the United States. Opdivo, a PD 1 […]

View full entry

Tags: alk, EGFR, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell, opdivo, PD-L1 levels, xalkori